Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype

Immunotherapy with histamine dihydrochloride and low-dose interleukin-2 (HDC/IL-2) reduces the risk of relapse in the post-chemotherapy phase of acute myeloid leukemia (AML). Here we report the results of exploratory analyses of the clinical efficacy of HDC/IL-2 in AML with focus on the impact of ka...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Malin S. Nilsson, Alexander Hallner, Mats Brune, Staffan Nilsson, Fredrik B. Thorén, Anna Martner, Kristoffer Hellstrand
Format:	Artigo
Jezik:	Inglês
Izdano:	Taylor & Francis Group 2020-01-01
Serija:	Human Vaccines & Immunotherapeutics
Teme:	acute myeloid leukemia histamine dihydrochloride il-2 immunotherapy relapse prevention normal karyotype
Online dostop:	http://dx.doi.org/10.1080/21645515.2019.1636598
Oznake:	Označite Brez oznak, prvi označite!